Background Eniluracil is an effective inactivator of dihydropyrimidine dehydrogenase, the initial and rate limiting enzyme in the catabohsm of fluorouracil The current study was done to determine the objective tumour response of a 28-day oral regimen of eniluracil-fluorouracil in patients with advanced breast cancer
Introduction
Patients with advanced breast cancer refractory to anthracychnes are frequently offered treatment with taxanes. However, there is no standard treatment for patients with advanced breast cancer that is refractory to both anthracyclines and taxanes Administration of 5-fiuorouracil (5-FU) by protracted continuous infusion is well tolerated and efficacious in treating patients with advanced breast cancer who have not responded to other chemotherapies [1, 2] 5-FU has to be administered via this route as it is rapidly metabolised in the liver and other tissues by dihydropynmidine dehydrogenase (DPD) However, coadministration of eniluracil, an effective inactivator of DPD [3] , and 5-FU enables low oral doses of 5-FU to be administered, resulting in predictable plasma concentrations comparable with those reported for continuous intravenous infusion of 5-FU [4] Oral chemotherapy allows the treatment to be taken at home, and avoids the need for central venous access and infusion This study (FUMB2004) was performed to evaluate the objective tumour response rate of a 28-day oral regimen of eniluracil-fluorouracil in patients with anthracycline-refractory (AR) or anthracycline-and taxanerefractory (ATR) advanced breast cancer. Secondary objectives were to evaluate the safety of the dosing regimen, and to estimate the duration of response, the duration of progression-free survival and the overall survival rate.
Patients and methods

Patients
The key admission criteria were
• Adult females with advanced breast cancer refractory to anthracychnes. or anthrdcychnes and taxanes • Karnofsky Performance Status of at least 70 • No history of another malignancy in the last five years • No more than three previous chemotherapy regimens • Informed consent
Study design
This was a multicentre. open-label phase II study conducted according to the latest version of the Declaration of Helsinki Patients received 10 mg/m 2 eniluracil and 1 mg/m 2 fluorouracil (supplied by Glaxo Wellcome Inc. USA) orally twice daily for the first 28 days of a 35-day treatment course. Study medications were taken together approximately every 12 hours Patients continued treatment courses until disease progression or unmanageable toxicity Dose modifications were based on drug-related toxicities in the preceding treatment course and the patient's current estimated creatrnine clearance [5] All sites of disease were assessed approximately every 10 weeks The tumour response definitions were adapted from, and adverse events were graded using criteria from the Southwest Oncology Group (SWOG)
[6] Time-to-event parameters were analysed using Kaplan-Meier product limit estimates
Results
One hundred six patients received study medication: 62 patients in the AR stratum, and 44 patients in the ATR stratum. The characteristics of the patients at baseline are shown in Table 1 .
The overall tumour response rate was 18% (19% in the AR and 16% in the ATR stratum; Table 2) In the AR stratum, 2 patients had a complete response, and 10 patients had a partial response; in the ATR stratum, 1 patient had a complete response, and 6 patients had a partial response The median duration of response was 23.6 weeks (95% CI 18.0-38.3 weeks) and was similar for patients in both strata. Overall, 38 patients had stable disease as their best response with a median duration of 19 7 weeks (95% CI. 17.4-28 7 weeks). The median duration of progression-free survival for all patients was 14.1 weeks (95% CI 10.1-19.1 weeks), and the median duration of survival was 42.0 weeks (95% CI: 36.4-53.3 weeks) Both of these parameters were slightly longer for patients in the AR stratum compared with those in the ATR stratum
The combination of eniluracil-fluorouracil was well tolerated in this study. No individual grade 3 or 4 nonhaematological adverse events considered possibly attributable to study medication occurred in > 3% of patients. The most common adverse events of any grade possibly attributable to study medication were: nausea (33%), diarrhoea (28%), and malaise and fatigue (27%) Adverse events that are common in 5-FU-containing regimens had a low overall incidence in this (0) 10 (16) 23 (37) 16 (26) 13 (21) 10 (16) 52 (84) 34 (55) 31 (50) 26 (42) 21 (34) 48 (77) 14 (23) ATR (n=44) 50 (31-67) 39 (89) 1 (2) 2 (5) 2 (5) 5 (11) 19 (43) 12 (27) 8 (18) 4 (9) 40 (91) 29 (66) 27 (61) 16 (36) 12 (27) 18 (41) 26 (59) Excluding the most recent anthracyclines and taxanes trial, mucositis (12%), skin rashes (6%), and hand-foot syndrome (5%). Grade 3 or 4 haematological toxicities were uncommon (^ 8% patients for any individual toxlcity) and grade 3 or 4 treatment-emergent clinical chemistry toxicities were also uncommon.
Discussion
It is difficult to compare the results of this study with those previously reported, because the definitions of refractory and related terms vary considerably among different trials. Generally in patients with pre-treated Abbreviations AR -anthracychne-refractory. ATR -anthracychne and taxane-refractory, n -number of patients, CI -confidence interval, NC -not calculated breast cancer, the response rate tends to decrease with increasing lines of salvage therapy. The overall response rate for all salvage therapies after failure to respond to a first-line anthracycline-containing regimen is estimated at only 11% [7] . The best and most consistent results reported for patients with strictly defined anthracyclinerefractory disease are with the taxanes [8] . The response rate seen in this study is comparable with studies using continuous infusion of 5-FU in patients with pre-treated advanced breast cancer (16%-53%) [1, 2, 9] . One of the advantages of oral eniluracil-fluorouracil treatment is the toxicity profile. In the current study there was a particularly low incidence of grade 3 or 4 toxicities. The overall incidence of adverse events was also low in the current study. The toxicity profile of eniluracil-fluorouracil also compares favourably with taxane therapy in similar settings. The incidence of grade 3 and 4 toxicities varies among different studies, but neutropenia can affect up to 95% of taxane-treated patients [10] There was also less toxicity compared with capecitabine (an oral 5-FU pro-drug) in patients with pachtaxel-refractory breast cancer [11] .
The inactivation of DPD by eniluracil improves the pharmacokinetic profile of oral 5-FU resulting in more predictable plasma concentrations of 5-FU and an increased plasma half-life Inactivation of DPD by eniluracil also improves the oral bioavailabihty of 5-FU enabling oral dosing [4, 12] . Eniluracil also reduces the formation of toxic catabolites of 5-FU thus decreasing 5-FU toxicity.
Treatment with oral eniluracil-fluorouracil was well tolerated by patients with advanced breast cancer. The efficacy data in this study were comparable with those of other published studies in this refractory patient population [1, 2, 9] . Strategies to further improve the efficacy of oral eniluracil-fluorouracil in patients with previously treated breast cancer could include raising the 5-FU dosage level and using oral eniluracil-fluorouracil in combination with other drugs including the taxanes
